* These authors contributed equally. † WHONET is a free software program developed by the World Health Organization (WHO) Collaborating Centre for Surveillance of Antimicrobial Resistance to support national surveillance activities in more than 120 countries (http://www.whonet.org/index.html). § https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/IA/INS/ ins-alerta-colombia-candida-auris.pdf. region (Atlántico, Bolívar, and Cesar). The median age of all patients was 36 years (interquartile range = 2-62 years), and 75 (61%) were male. Children aged 0-18 years accounted for 39 (32%) cases, including 23 (19%) in infants aged <1 year. The majority (68; 56%) of cases were reported from the northern region, and 30 (24%) were reported from the central region. Isolates were recovered from blood (74; 60%), urine (11; 9%), respiratory specimens (10; 8%), the gastrointestinal tract (7; 5%), and other body fluids and body sites (8; 7%). For 13 (11%) cases, no information was available about the source of the C. auris isolate.
The VITEK 2 system had been used for yeast identification in 21 (75%) of 28 medical institutions. Four institutions used MicroScan (one), BD Phoenix (one), and Bruker MALDI-TOF Biotyper systems (two), and for three institutions, information about the identification method was not available. Six (4%) of 123 C. auris isolates were correctly identified, all by a clinical laboratory that used MALDI-TOF Biotyper (2). C. auris was most frequently misidentified as C. haemulonii (94; 76%), including 69 (97%) of 71 isolates identified by VITEK 2, all 23 isolates identified by BD Phoenix, and two of eight identified by MALDI-TOF Biotyper. Automated systems were unable to report a species for eight (7%) isolates (two by VITEK 2, four by MicroScan, and two by a system whose method was not reported). Thirteen C. auris isolates, all tested by MicroScan, were misidentified as other yeasts (Candida albicans, Candida guilliermondii, Candida parapsilosis, and Rhodotorula rubra).
Antifungal susceptibility testing was performed on 93 (76%) isolates ¶ (2, 5) . Overall, 28 (30%) were resistant to fluconazole, 20 (22%) to amphotericin B, one (1%) to anidulafungin (an echinocandin), and one to both amphotericin B and anidulafungin.
Infections caused by C. auris are occurring in Colombia; the pathogen has been present in Columbia since at least 2015, and case counts are increasing. The number of reported cases likely does not reflect the true number of infected and colonized persons because of underreporting and underdiagnosis, as well as misdiagnosis as other yeast species (6) . To contain the spread of C. auris in Colombia, INS updated the C. auris national clinical alert in July 2017 specifying which yeast isolates must be sent to INS for confirmation and mandating that medical facilities implement enhanced infection control ¶ The broth microdilution method was used for azoles and echinocandins and Etest for amphotericin B; susceptibility breakpoints used were those described by CDC.
practices, including using contact precautions and single rooms for patients with C. auris infections, minimizing the number of health care personnel in contact with infected patients, and daily and terminal cleaning of patient rooms and medical equipment with a disinfectant effective against Clostridium difficile spores** (2). Clinical laboratories should be aware that automated laboratory systems might incorrectly identify C. auris, particularly as C. haemulonii, although the species reported depends on the system (2).
